2017 American Transplant Congress
Occult Hepatitis C Virus in Recipients of Kidney Transplantation: Prevalence and Clinical Implications.
Occult HCV infection (OCI) is characterized by the presence of HCV- RNA in liver or in peripheral blood mononuclear cells in the absence of serological…2017 American Transplant Congress
Liver Allograft Hepatitis and Graft Loss After Hepatitis C Clearance.
Surgery, University of Maryland School of Medicine, Baltimore, MD
Successful HCV therapies should improve inferior outcomes of liver transplantation (LT) for HCV cirrhosis. We hypothesize certain patients may be predisposed to heterologous immunity that…2017 American Transplant Congress
Post Transplant Outcomes in Hepatitis C Positive Patients.
Montefiore Medical Center, Bronx
Hepatitis C (HCV) is associated with increased morbidity and mortality after kidney transplant (KTx). We aimed to assess outcomes of HCV positive patients at our…2017 American Transplant Congress
Transplantation of Hepatitis C Kidneys to Hepatitis C Recipients Confers Significantly Shorter Waiting Times in the Era of the New Kidney Allocation System.
Nashville VA Medical Center, Nashville, TN
Background: Prior to the new KAS, transplantation with HCV+ compared to HCV- kidneys provided shorter waiting times on the deceased donor list. In the current…2017 American Transplant Congress
Pharmakokinetics of Daclatasvir, Sofosbuvir and GS-331007 in a Prospective Cohort of HCV Positive Kidney Transplant Recipients.
BackgroundLimited data exist on the pharmacokinetic (PK) profile of novel direct acting antivirals in kidney transplant recipients (KTR). Here we report the PK of combinated…2017 American Transplant Congress
Transplanting Hepatitis C Kidneys into Negative KidnEy Recipients [THINKER] Trial.
University of Pennsylvania, Philadelphia
Background: More than 500 kidneys from HCV+ deceased donors are discarded each year, even though direct acting antiviral therapies have cure rates exceeding 95%. We…2017 American Transplant Congress
The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.
University of Maryland Medical Center, Baltimore, MD
Background: Renal transplant recipients (RTRs) with HCV are at an increased risk of graft rejection, making treatment of HCV in this population of the utmost…2017 American Transplant Congress
EXPANDER-1: Exploring Renal Transplants Using Hepatitis-C Infected Donors for HCV-Negative Recipients.
Kidneys from hepatitis C-infected (HCV+) donors are underutilized in an era of severe organ shortage. In an effort to expand the donor pool, we evaluated…2017 American Transplant Congress
Single-Center Initial Experience in Treating Chronic Hepatitis C in Kidney Transplant Recipients.
Nephrology and Kidney Transplant Department, ISCMPA, Porto Alegre, RS, Brazil
Chronic hepatitis C (HCV) infection is a prevalent condition in end-stage renal disease and presents an important clinical challenge in kidney transplant recipients (KTR). Interferon-based…2017 American Transplant Congress
Use of Ledipasvir/Sofosbuvir with or without Ribavirin in Patients Post-Liver Transplant: Evaluation of Real-World Datasets.
PURPOSE: Post-liver transplant(LT) patients with HCV are considered a difficult-to-treat population. Ledipasvir/sofosbuvir(LDV/SOF) +ribavirin(RBV) for 12 weeks is approved in GT1 LT recipients based on the…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 28
- Next Page »